Tempus IHC logistics overview (powered by NeoGenomics)

Tempus offers add-on IHC testing to provide additional insights to help inform your patient care.

Clinical Guideline Recommended

Tempus offers IHC tests that are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician's discretion.



Epithelial Ovarian Cancer (EOC): Recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.¹

 HER2 with reflex to ERBB2 FISH testing (powered by NeoGenomics)

Breast: Recommended for all new primary or newly metastatic breast cancers.²

Reflex to FISH with IHC score of 2+.2,3

Gastric: Recommended for all gastric cancer patients at the time of diagnosis if metastatic disease is documented or suspected.^{4,†}

Reflex to FISH with IHC score of 2+.4,5

Other Cancer Specimens: IHC scored according to ASCO/CAP gastric guidelines^{5,6}, no reflex to FISH available.

Ordering & Reporting

Flexible ordering options are available via online ordering through Tempus Hub or paper requisition.

Available as add-on tests to xT solid tumor DNA seq or xR RNA seq.

Results from Tempus are expected within 2 days of NeoGenomics receiving the specimen.*

In the event of an insufficient tissue, you will receive a TNP (tissue not processed) or QNS (quality not sufficient) report from Tempus on behalf of NeoGenomics.

- 1 NCCN Clinical Practice Guidelines in Oncology. Ovarian. Version 1.2024.
- 2 NCCN Clinical Practice Guidelines in Oncology. Breast. Version 2.2024.
- 3 Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867-3872.
- 4 NCCN Clinical Practice Guidelines in Oncology. Gastric. Version 1.2024.
- 5 Bartley AN, Washington MK, Ventura CB, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345-1363.
- 6 Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor 02 Phase II Trial. J Clin Oncol. 2024;42(1):47-58.
- 7 NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1.2024.
- 8 NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 1.2024.

Specimen Requirements for Pathology

All tissue samples are sent to Tempus, where they will be cut (if needed) and slides will be sent to NeoGenomics for IHC testing.

Send one Tempus tissue kit for both xT/xR and IHC testing.



FFPE Block (preferred collection method) or FFPE Slides. Use positively-charged, unbaked slides and 10% NBF fixative (no decalcified specimens)

FOLR1 (FRα) IHC	Three to four (3-4) unstained slides cut at 4
	microns is preferred, 5 microns acceptable.
	Minimum of 100 tumor cells needed to
	interpret staining.

HER2 IHC	Six to seven (6-7) unstained slides cut at 4
with reflex to ERBB2 FISH	microns is preferred, 5 microns acceptable.
for breast and gastric	Minimum of 100 tumor cells needed to
cancers†	interpret staining.

HER2 IHC only	Three to four (3-4) unstained slides cut at 4
for other cancer types	microns is preferred, 5 microns acceptable.
	Minimum of 100 tumor cells needed to
	interpret staining.

*In accordance with appropriate ASCO/CAP and NCCN guidelines, your order will be reflexed based on the IHC scores listed for the breast or qastric cancer type $^{2-6}$

*HER2 testing is recommended for patients with metastatic colorectal cancer (CRC). CRC specimens are not scored in accordance with CRC guidelines ^{7,8}, but instead fall under the HER2 gastric scoring criteria and remain candidates for FISH reflex

*For HER2 IHC only; reflex to ERBB2 FISH adds an additional 3-5 days

We help provide access to our tests for patients in financial need. Patients can complete the financial assistance application online at access.tempus.com or call 800.739.4137 to speak to a member of our team.

If you have any questions on our comprehensive portfolio please contact your Tempus Representative or email support@tempus.com